Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11533429 | 0.89 | CYP2C9 (0.65) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL167573 | 0.83 | MEN1 (0.73) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL8602062 | 0.82 | CYP2C9 (0.59) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL5987795 | 0.81 | MAPT (0.68) | CYP2C9CYP2C19KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL31160290 | 0.80 | TSHR (0.58) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL6656120 | 0.80 | TSHR (0.58) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL376127 | 0.80 | CYP1A2 (0.57) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL3457884 | 0.80 | TSHR (0.57) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL3662909 | 0.80 | SMN1; SMN2 (0.71) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 | |
| SCHEMBL258716 | 0.80 | CYP2C9 (0.62) | CYP2C9CYP2C19TSHRCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204808-A1 | TARGET ENGAGEMENT ASSAY FOR RAS PROTEINS | Promega Corporation (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-7700605-B2 | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | FLOHR STEFANIE | 2008-09-04 | — | — | US | disclosed |
| CN-101228136-A | 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| EP-1907368-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009715-A1 | 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214548-A1 | 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors | USP2, UCHL3, UCHL5 | CYP2C9 1884/4885CYP2C19 2052/4885TSHR 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.